SENP7

Across TCGA pan-cancer cohorts, SENP7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SENP7 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher SENP7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SENP7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LAML, UCEC, and PRAD are the cancer types where SENP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.111	0.572	.010	12	view →
UCEC	DFS	Median	II,III,IV	0.873	0.304	.023	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SENP7–LAML (DFS)

Open the LAML breakdown →